GENE ONLINE|News &
Opinion
Blog

2021-08-26| InterviewsSpecial

Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara

by Kathy Huang
Share To
With two COVID-19 vaccines gaining emergency use approvals, mRNA technology has come into focus over the past year. RNA technology encompasses a wide range of modalities and RNA editing is one among them. Although the technique is still being perfected and hasn’t become clinically viable, its high efficiency and safety over DNA editing is expected to make a splash in the near future.

We interviewed Professor Toshifumi Tsukahara, an expert in RNA editing to know more about the current challenges and future opportunities in the field.

GO Prime with only $1.49 now

LATEST
Novel RAGE Antagonist Stirs Hopes for Countering Diabetic Complications
2021-12-07
AstraZeneca Blocks Private Equity Buyout of Swedish Pharma Sobi
2021-12-06
Coherent Biopharma, WuXi STA Collab Takes a Crack at Peptide-Drug Conjugates
2021-12-06
How CDMOs are Restructuring the Biopharma Landscape – An Interview with Bobby Sheng
2021-12-06
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
2021-12-03
Novartis, UCB Take Aim at Parkinson’s Disease Under $1.65 Billion Collab
2021-12-03
Atara Biotherapeutics’ First-In-Class Allogeneic T-Cell Therapy Accepted for EMA Review
2021-12-02
EVENT
2021-12-13
63rd ASH ANNUAL MEETING AND EXPOSITION
Georgia, USA
2021-12-28
BIOHK2021
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!